keyword
MENU ▼
Read by QxMD icon Read
search

Relypsa

keyword
https://www.readbyqxmd.com/read/26798850/patiromer-a-significant-advance-in-the-management-of-hyperkalemia
#1
REVIEW
D M Paton
The U.S. Food and Drug Administration (FDA) approved patiromer to treat hyperkalemia on October 21, 2015, making it the first agent approved for this condition in 50 years. Patiromer was developed by Relypsa, Inc. The active ingredient is patiromer sorbitex calcium which consists of the active moiety, patiromer, a nonabsorbed potassium-binding polymer, and a calcium-sorbitol counterion. In the colon, patiromer exchanges calcium for potassium thus causing a fall in serum potassium. Trials have shown that patiromer reduces serum potassium in patients with mild, moderate and moderate to severe hyperkalemia to the normal range...
December 2015: Drugs of Today
https://www.readbyqxmd.com/read/26456884/patiromer-a-clinical-review
#2
REVIEW
Ann G Montaperto, Mona A Gandhi, Lauren Z Gashlin, Melanie R Symoniak
IMPORTANCE: Patiromer FOS (for oral suspension), formerly known as RLY5016, is pending FDA approval for the treatment of hyperkalemia. Once approved, patiromer, as well as a second agent known as sodium zirconium cyclosilicate (ZS-9), will be among the new therapeutic options available to treat hyperkalemia in over 50 years. OBJECTIVE: The primary objective of this review is to analyze the efficacy and safety of patiromer to treat hyperkalemia and compare its pharmacokinetics to currently available sodium polystyrene sulfonate (SPS) therapy...
2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/25415805/patiromer-in-patients-with-kidney-disease-and-hyperkalemia-receiving-raas-inhibitors
#3
RANDOMIZED CONTROLLED TRIAL
Matthew R Weir, George L Bakris, David A Bushinsky, Martha R Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ-Schmidt, Lance Berman, Bertram Pitt
BACKGROUND: Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to less than 6.5 mmol per liter received patiromer (at an initial dose of 4...
January 15, 2015: New England Journal of Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"